CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline

Stock Information for CNS Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation
CNS Pharmaceuticals Issues Letter to Shareholders
CNS Pharmaceuticals Announces CEO Transition
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
IBN Announces Latest Episode of The BioMedWire Podcast Featuring John Climaco, CEO of CNS Pharmaceuticals Inc.

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.